EMIG Logo

What We Do

What do we do?

We support our Members in navigating the complex journey from regulatory approval to patient access by engaging with key decision-makers who shape UK market access.

This means understanding the challenges that individual companies experience and providing them with the practical help and guidance they need to achieve patient access.

Our aim is to drive meaningful change that makes the UK an attractive place for businesses to invest and launch new and exciting medical advances.

  • Voice of The Industry

    Voice of the Industry

    EMIG represents its members with Government, regulatory bodies, HTA, and the NHS to improve patient access to a wide range of innovative medicines.

    In Government, we work with the UK's Department of Health and Social Care (DHSC), the Office for Life Sciences (OLS), the Department of Business and Trade, and the Department of Science, Innovation and Technology (DST).

    We work in partnership with the HRA, MHRA, NICE and the NHS and represent our members in dialogue with a wide range of patient organisations.

  • Networking

    Networking

    • Networking is a critical activity for developing new ideas and creating business opportunities.
    • On request, we connect companies with other Members who can provide practical assistance to identify in-licensing and outsourcing opportunities.
    • Our Quarterly Meetings are always in-person and attract an audience of c. 140 senior managers and directors.
    • Our Annual Parliamentary Dinner is held in central London in November and attracts an audience c. 160-180 which includes politicians, stakeholders and Members. Our special guest speakers are chosen to provide political insight with a little humour.
    • Members can access future events/dates via email invitations and the EMIG web portal.
  • Expert Advice

    Expert Advice

    • EMIG experts can provide help and advice across all business areas.
    • Advice has included outsourcing services e.g. acquisition or divestment; regulatory issues; finance; legal affairs; engaging with patient organisations; sales training; industry Code of Practice.
  • Policy, Information and Intelligence

    Policy, Information and Intelligence

    Our Special Interest Groups (SIGs) make a vital contribution to our policy positions by sharing information and intelligence to determine our direction on the myriad issues companies face.

    The SIGs meet 3-4 times per year both virtually and face to face, are chaired by an expert in the subject and ably assisted by a Steering Group.

  • Devolved Nations

    Devolved Nations

    We have active Special Interest Groups in each of the devolved nations.

    EMIG has a seat on the All Wales Therapeutic & Toxicology Committee (AWTTC).

    And has a representative on the Scottish Medicines Consortium User Group Forum.

  • Europe

    Europe

    Although the UK has exited the EU, many companies still need to do business with the EU. It is vital therefore that we understand and keep up to date with the continuing political, regulatory and HTA developments across Europe.

    Leslie Galloway is Vice President of EUCOPE, a Brussels based association that operates across Europe. This means we have close contact with senior pharma people who are close to inter alia the European Parliament, the European Commission and the European Medicines Agency (EMA).

    In turn, we can provide help for those Members who need to understand the European market and the major players.